Repositioning Candidate Details
| Candidate ID: | R0644 |
| Source ID: | DB04915 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Idronoxil |
| Synonyms: | 3-(4-hydroxyphenyl)-2H-chromen-7-ol; Dehydroequol; Haginin E; Idronoxil; Phenoxodiol |
| Molecular Formula: | C15H12O3 |
| SMILES: | OC1=CC=C(C=C1)C1=CC2=C(OC1)C=C(O)C=C2 |
| Structure: |
|
| DrugBank Description: | Idronoxil is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors. |
| CAS Number: | 81267-65-4 |
| Molecular Weight: | 240.254 |
| DrugBank Indication: | Intended for the treatment of various forms of cancer. |
| DrugBank Pharmacology: | Phenoxodiol inhibits proliferation of many cancer cell lines and induces apoptosis by disrupting FLICE-inhibitory protein, FLIP, expression and by caspase-dependent and -independent degradation of the X-linked inhibitor of apoptosis, XIAP. In addition, phenoxodiol sensitizes drug-resistant tumour cells to anticancer drugs including paclitaxel, carboplatin and gemcitabine. |
| DrugBank MoA: | The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Results from one study (PMID: 17904534) indicate that plasma membrane electron transport (PMET) may be a primary target for phenoxodiol in tumour cells and in activated T cells. |
| Targets: | Ecto-NOX disulfide-thiol exchanger 2 |
| Inclusion Criteria: | Therapeutic strategy associated |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|